Catalysing cancer control through multisectoral and shared value partnerships

Catalysing cancer control through multisectoral and shared value partnerships

The sustained commitment and engagement of all UICC partners in 2021 allowed UICC to pursue its important agenda despite the pandemic. UICC has continued to drive impactful activities and programmes to empower and connect the cancer community, promoted greater equity and ensured that cancer remains a priority on the global health and development agenda.

During the year, UICC further diversified its partnership base by welcoming new partners such as Revolution Watch, Becton, Dickinson and Company, GE Healthcare and BeiGene. UICC was also able to deepen the engagement with existing partners through World Cancer Day, the World Cancer Leaders’ Summit and the capacity building activities. For example, AstraZeneca organised a World Cancer Day Employee Donation Programme and Bristol Myers Squibb once again renewed its commitment to UICC and its members in Europe through the Country 2 Country Ride 4 Cancer. Both initiatives engaged the company’s staff and benefitted the cancer community.

Thanks to the robust partnership with the American Society for Clinical Pathology (ASCP) and the engagement and support of UICC partners such as the National Cancer Institute in the US (NCI USA), the Canadian Partnership Against Cancer (CPAC), the French National Cancer Institute (INCa), Novartis, MSD, Daiichi Sankyo and others, UICC was able to drive impactful discussions around the nexus between innovation and equity during the World Cancer Leaders’ Summit. Together with longstanding partners like Sanofi, the Dutch Cancer Society (KWF), Cancer Research UK (CRUK), Roche and Pfizer, UICC moved the needle on specific areas of work such as leadership, cancer and ageing, tobacco control, women’s cancers and patient engagement, enabling the cancer community to be more effective and impactful. UICC is grateful that so many organisations wish to work with its members to extend the impact and reach of its work around the world and recognises the critical role that partners play in supporting UICC’s mission and expanding UICC’s scope and impact.

“Drug-resistant infections impact the care and treatment of millions of patients every year. And unfortunately, cancer patients are not only impacted but can be most affected by these infections. By partnering with UICC to raise awareness and to create impactful programmes, we have informed and educated advocates to drive innovation and policy to slow the impact of drug-resistant infections. Our future depends on what we do today.”

Becton, Dickinson, and Co.

Catalysing cancer control through multisectoral and shared value partnerships

“At Roche, we are extremely proud of our partnership with the UICC. Cancer is one of the most profound challenges we have in healthcare, and while we have made extraordinary advances in treatment, we are still not reaching millions of people suffering from cancer all over the world. Each time I spend time with Cary and the UICC community, I become more confident that we can change this. The work they are doing to unite the world's cancer community and advance cancer care is genuinely inspiring."

Teresa Graham, Head of Global Product Strategy, Roche Pharmaceuticals "This year represents an exciting expansion of the partnership between Bristol Myers Squibb (BMS) and the UICC via our Country 2 Country 4 Cancer (C2C4C) bike rides. With our inaugural 2022 Continent 2 Continent 4 Cancer ride in Latin America along with our C2C4C ride in Europe, we will have more employees riding more kilometers and raising more funds for the UICC and its member organisations. Together, we unite and ride for patients, supporting the cancer community and demonstrating our longstanding commitment to cancer research."

Catherine Owen, Senior Vice President and Head of Major Markets, BMS Winselow Tucker, Senior Vice President and Head of Intercon, BMS “The Dutch Cancer Society has proudly supported the European CEO programme, which has generated a larger cooperation between UICC members in Europe, especially on cancer research in the region, identified as a key issue seeking more and better international coordination. Thank you to UICC for facilitating this discussion and suggesting concrete steps forward to reimagine cancer and define together the future of cancer implementation science in Europe.”

Johan van de Gronden, CEO, Dutch Cancer Society (KWF)